Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Free Fatty Acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43892   clinical trials with a EudraCT protocol, of which   7299   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Free Fatty Acid. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-002386-37 Sponsor Protocol Number: IVN3ICD Start Date*: 2007-08-24
    Sponsor Name:Department of Cardiology, Aalborg Hospital
    Full Title: Intravenous infusion of n-3 polyunsaturated fatty acids and ventricular tackycardi in patients with implantable cardioverter defibrillator (ICD)
    Medical condition: Patients with an implantable cardioverter defibrillator (ICD-unit) for treatment for cardiac ventricular arrhythmias and for prevention of sudden cardiac death
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002656-32 Sponsor Protocol Number: HYPOTESIS Start Date*: 2013-07-23
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel
    Full Title: The impact of free fatty acid (FFA-) suppression on myocardial lipids and function in patients with type 2 diabetes
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004342-42 Sponsor Protocol Number: 201302 Start Date*: 2014-03-26
    Sponsor Name:Medisch Centrum Alkmaar
    Full Title: The effect of fish oil supplements on hemorheological parameters and walking distance in patients with intermittent claudication
    Medical condition: Patients suffering from intermittent claudication
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004866 10067825 Peripheral arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000367-25 Sponsor Protocol Number: AURIGA Start Date*: 2019-04-17
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Acute effect of parenteral rehydration solution commonly used in children with acute gastroenteritis on acid-base balance, free-fatty acids metabolism and glucose homeostasis
    Medical condition: Dehydration and metabolic acidosis due to acute gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012174 Dehydration PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000322-19 Sponsor Protocol Number: UX007-CL202 Start Date*: 2016-06-06
    Sponsor Name:Ultragenyx Pharmaceutial Inc.
    Full Title: An Open-label Long-Term Safety and Efficacy Extension Study in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies
    Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-004404-21 Sponsor Protocol Number: SLE-Omega Start Date*: 2004-12-10
    Sponsor Name:GreenPark Healthcare Trust [...]
    1. GreenPark Healthcare Trust
    2. Queens University Belfast
    Full Title: Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002836-18 Sponsor Protocol Number: EPA/POL/03 Start Date*: 2006-10-09
    Sponsor Name:S.L.A. Pharma (UK) Ltd
    Full Title: A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid.
    Medical condition: Familial adenomatous polyposis (FAP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059327 Familial adenomatous polyposis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003575-34 Sponsor Protocol Number: 301084 Start Date*: 2018-11-29
    Sponsor Name:Professor, Ph.d. MD. Filip Krag Knop
    Full Title: Treatment of bile acid malabsorption with liraglutid
    Medical condition: Bile acid malabsoprtion is a disease in which there is a large spill-over of bileacids to the larger intestines. This causes watery diarrheas and abdominal symptoms.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10080051 Bile acid diarrhoea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002597-30 Sponsor Protocol Number: NIASPAN-DD-2005 Start Date*: 2006-01-02
    Sponsor Name:Gesellschaft für Wissens- und Technologietransfer der TU Dresden mbH
    Full Title: Placebokontrollierte Untersuchung zur Wirkung von Nikotinsäure auf die Dyslipidämie bei Metabolischem Syndrom und das Arterioskleroserisiko
    Medical condition: Dyslipidemia (Hypertriglyzeridemia and/or low HDL-cholersterol) with metabolic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020943-10 Sponsor Protocol Number: GA10/9312 Start Date*: 2011-03-16
    Sponsor Name:University of Leeds
    Full Title: A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme...
    Medical condition: colorectal adenoma (polyp)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10048841 Bowel cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002263-15 Sponsor Protocol Number: LIXISL07016 Start Date*: 2014-10-10
    Sponsor Name:sanofi aventis S.p.A
    Full Title: Effects of GLP-1 Receptor Agonist Lixisenatide on Post-prandial Lipid Profile in Obese Type 2 Diabetic Patients
    Medical condition: Effect of GLP-1 receptor agonist lixisenatide on post-prandial lipid profile in obese patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002321-74 Sponsor Protocol Number: 20061218 Start Date*: 2007-08-29
    Sponsor Name:Aarhus University Hospital, Skejby sygehus
    Full Title: Effect of 4 weeks treatment with Acipimox on left ventricular function, work capacity, insulin sensitivity and substrate metabolism in patients with chronic heart failure
    Medical condition: chronic stable heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004485-14 Sponsor Protocol Number: 20060810 Start Date*: 2007-01-18
    Sponsor Name:Aarhus University Hospital, Skejby sygehus
    Full Title: Metabolic Modulation as treatment of acute heart failure in patients
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005076-41 Sponsor Protocol Number: E7001-H002 Start Date*: 2006-11-14
    Sponsor Name:Hvidovre Hospital
    Full Title: Effect of nasal GLP-1 versus placebo on fasting state and postprandial hyperglycaemia in type 2 diabetes. A single centre, prospective, placebo controlled clinical trial evaluating efficacy and sa...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002243-27 Sponsor Protocol Number: 305/2004 Start Date*: 2004-08-14
    Sponsor Name:Clinical Pharmacology
    Full Title: Vascular effects of peroxisome proliferator–activated receptor gamma stimulation with rosiglitazone during exogenousely elevated free fatty acid concentrations in healthy volunteers
    Medical condition: healthy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003820-58 Sponsor Protocol Number: D1690C00063 Start Date*: 2018-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, randomized, parallel group, phase IV study to investigate the effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency and myocardial contractile work in type 2 d...
    Medical condition: type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005634-12 Sponsor Protocol Number: EPA/POL/02 Start Date*: 2006-06-12
    Sponsor Name:S.L.A. Pharma (UK) Ltd
    Full Title: The effect of two dose levels of eicosapentaenoic acid (EPA) on apoptosis and cell proliferation in the colonic mucosa of patients with a history of colonic polyps.
    Medical condition: Sporadic colonic adenomata
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001034-14 Sponsor Protocol Number: 07/Q0803/31 Start Date*: 2007-08-10
    Sponsor Name:St George's Healthcare NHS Trust [...]
    1. St George's Healthcare NHS Trust
    2. SLA Pharma
    Full Title: The effect of omega-3 fatty acids on Barrett's oesophagus
    Medical condition: Barrett's oesophagus refers to changes in the lining of the lower oesophagus in response to injury caused by gastric reflux. It is a pre-malignant condition and has a well established link with ad...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004134 Barrett's esophagus LLT
    9.1 10004136 Barrett's oesophagitis with dysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-000825-35 Sponsor Protocol Number: U1111-1167-2731 Start Date*: 2015-08-27
    Sponsor Name:Rigshospitalet Blegdamsvej
    Full Title: The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study
    Medical condition: Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; ...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 29 16:18:49 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA